Adjuvant systemic treatment for individual patients with triple negative breast cancer

Oakman, Catherine; Moretti, Erica; Galardi, Francesca; Biagioni, Chiara; Santarpia, Libero; Biganzoli, Laura; Leo, Angelo Di

doi:10.1016/s0960-9776(11)70311-3

Cited by 14 publications

(10 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, more than one-half of TNBCs do not respond to chemotherapy. 31 Predictably, patients who do not obtain a complete pathologic response have a high likelihood of disease relapse, frequent distant metastases, and a poorer prognosis compared with patients who have hormonal receptor-positive breast cancer. As compared with patients who have non-TNBCs, patients with TNBCs are younger at disease onset (,50 years) with a higher tumor grade at diagnosis and a higher rate of developing metastatic disease.…”

Section: Distinguishing Between Papillary Lesionsmentioning

confidence: 99%

Update on Immunohistochemical Analysis in Breast Lesions

Peng¹,

Butt²,

Chen³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-The utility of immunohistochemistry (IHC) in breast lesions needs to be updated with exceptions among these lesions. Biomarker studies with IHC in triple-negative breast carcinoma may help develop targeted therapies for this aggressive breast cancer. The distinction of metastatic lung adenocarcinoma to the breast and invasive breast carcinoma has significant prognostic and therapeutic implications. The determination can be challenging because both primary tumors can express estrogen receptor and/or HER2 by IHC, creating a diagnostic dilemma.Objectives.-To provide a practical update on the use of IHC markers in differential diagnoses in breast lesions, including benign, atypical, precancerous, and malignant tumors; to highlight recently published research findings on novel IHC markers in triple-negative breast carcinoma cases; and to reinforce the importance of IHC use as an ancillary tool in distinguishing metastatic lung adenocarcinoma to the breast from primary breast carcinoma using real case examples.Data Sources.-PubMed (US National Library of Medicine, Bethesda, Maryland) literature review and authors' research data and personal experiences were used in this review.Conclusions.-Immunohistochemistry has an important role in making differential diagnoses in breast lesions in morphologically equivocal settings; recognizing IHC expression status in the exceptions among these lesions will aid in the correct diagnosis of challenging breast cases. Studies suggest that androgen receptor, p16, p53, GATA3, and PELP1 may have potential diagnostic, prognostic, and predictive value in triple-negative breast carcinoma cases; these findings may provide insight and a greater understanding of the tumor biology in triple-negative breast carcinomas. In distinguishing metastatic estrogen receptor-positive or HER2 þ lung adenocarcinoma to the breast from primary breast carcinoma, napsin A, TTF-1, and GATA3 comprise a useful IHC panel.

show abstract

Section: Distinguishing Between Papillary Lesionsmentioning

confidence: 99%

Update on Immunohistochemical Analysis in Breast Lesions

Peng¹,

Butt²,

Chen³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Studies on neoadjuvant chemotherapy have shown that TNBC patients with pathological complete response (pCR) to treatment correlate with good clinical outcomes, with rates similar to non-TNBC patients. However, most TNBC patients (63%) have residual disease after treatment, showing a peak risk of relapse at around three years posttreatment, as well as an increased mortality rate [74%] [Carey et al, 2007;Dent et al, 2007;Cheang et al, 2008;Liedtke et al, 2008;Dent et al, 2009;Oakman et al, 2011;Andre and Zielinski 2012;Yu et al, 2013]. Although there are two TNBC patient groups: chemotherapysensitive and chemoresistant, the mechanism of this differing treatment response is unknown and so there is a clear need to resolve these differences and/or to identify specific targets as the basis for future therapies.…”

Section: ;mentioning

confidence: 99%

MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer

Tormo

Pineda

Serna

et al. 2015

J of Cellular Biochemistry

View full text Add to dashboard Cite

Thirteen miRNAs common to all three lines were modified, in addition to 25 that were specific to triple negative cell lines, and 69 that changed only in the luminal-A cell line. This altered expression pattern seemed to be more strongly related to the breast cancer subgroup than to the treatment. The analysis of target genes revealed that cancer related pathways were the most affected by these miRNAs, moreover many of them had been previously related to chemotherapy resistance; thus suggesting follow-up studies. Additionally, through functional assays, we showed that miR-548c-3p is implicated in doxorubicin-treated MCF-7 cell viability, suggesting a role for this miRNA in resistance.

show abstract

“…8 Unfortunately, standard chemotherapy compounds are rarely effective and TNBC tumors often lead to incurable metastatic disease. 7,9,10 …”

Section: Introductionmentioning

confidence: 99%

Phytochemicals potently inhibit migration of metastatic breast cancer cells

et al. 2015

View full text Add to dashboard Cite

Cell migration is a major process that drives metastatic progression of cancers, the major cause of cancer death. Existing chemotherapeutic drugs have limited efficacy to prevent and/or treat metastasis, emphasizing the need for new treatments. We focus on triple negative breast cancer (TNBC), the subtype of breast cancer with worst prognosis and no standard chemotherapy protocols. Here we demonstrate that a group of natural compounds, known as phytochemicals, effectively block migration of metastatic TNBC cells. Using a novel cell micropatterning technology, we generate consistent migration niches in standard 96-well plates where each well contains a cell-excluded gap within a uniform monolayer of cells. Over time, cells migrate into and occupy the gap. Treating TNBC cells with non-toxic concentrations of phytochemicals significantly blocks motility of cells. Using a molecular analysis approach, we show that anti-migratory property of phytochemicals is partly due to their inhibitory effects on phosphorylation of ERK1/2. This study provides a framework for future studies to understand molecular targets of phytochemicals and evaluate their effectiveness in inhibiting metastasis in animal models of cancer.

show abstract

Adjuvant systemic treatment for individual patients with triple negative breast cancer

Cited by 14 publications

References 58 publications

Update on Immunohistochemical Analysis in Breast Lesions

Update on Immunohistochemical Analysis in Breast Lesions

MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer

Phytochemicals potently inhibit migration of metastatic breast cancer cells

Contact Info

Product

Resources

About